January 19, 2022
Life Sciences
  • Pfizer Inc. said its COVID-19 antiviral pill, Paxlovid, was effective against the omicron variant in three separate lab tests. The development is an encouraging sign given some other COVID-19 treatments appear not to work as well. Even so, supply of Paxlovid remains limited. Pfizer said it expects to make 120 million courses of the drug globally by the end of the year. (Articles here and here)